ALLMedicine™ Prostate Cancer Center
Research & Reviews 87,209 results
https://doi.org/10.2967/jnumed.120.258533
Journal of Nuclear Medicine : Official Publication, Socie... Treiber H, Koenig A et. al.
May 15th, 2021 - 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we des...
https://doi.org/10.2967/jnumed.121.262120
Journal of Nuclear Medicine : Official Publication, Socie... Barbato F, Fendler WP et. al.
May 15th, 2021 - Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework...
https://doi.org/10.1007/s00345-021-03723-4 10.1097/CCO.0000000000000172 10.1093/annonc/mdv267 10.1038/nature05874 10.1158/1078-0432.CCR-13-1989 10.1093/nar/gkq1027 10.1146/annurev-pathol-012513-104715 10.1038/nrg2634 10.1002/pros.21276 10.1002/iub.1281 10.1038/onc.2011.624 10.1016/j.febslet.2015.04.037 10.1002/pros.22961 10.1093/nar/gni178 10.1038/onc.2012.55 10.1007/s11010-013-1882-5 10.1186/1479-5876-11-302 10.1038/nmeth.3014 10.1261/rna.036475.112 10.1038/bjc.2013.131 10.1177/1756287214555336 10.1186/1471-2490-13-58 10.1016/j.eururo.2016.08.002 10.1056/NEJMoa1315815 10.1016/j.biocel.2014.06.013 10.1158/0008-5472.CAN-15-0381 10.1038/nrurol.2015.13 10.1002/jcp.24510 10.1002/pros.22466 10.1093/clinchem/hvaa095
World Journal of Urology; Rönnau CGH, Fussek S et. al.
May 15th, 2021 - Prostate cancer (PCa) is a leading cause of cancer-related death. Upon androgen-deprivation therapy, the disease may progress further to castration-resistant PCa (CRPC) with a poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs, which pla...
https://doi.org/10.1002/cam4.3932
Cancer Medicine; Getaneh AM, Heijnsdijk EA et. al.
May 15th, 2021 - The introduction of multiparametric magnetic resonance imaging (mpMRI) and MRI-guided biopsy has improved the diagnosis of prostate cancer. However, it remains uncertain whether it is cost-effective, especially in a population-based screening stra...
https://doi.org/10.1007/s00330-021-08021-6 10.1016/j.eururo.2019.02.033 10.6004/jnccn.2018.0036 10.1016/j.juro.2016.06.079 10.1148/radiol.2019182946 10.1001/jamanetworkopen.2019.8427 10.1016/j.eururo.2020.06.015 10.1007/s00330-016-4635-5 10.1097/JU.0000000000001200 10.1056/NEJMoa1801993 10.1016/j.juro.2018.07.001 10.18632/oncotarget.26100 10.1007/s00330-017-4805-0 10.1109/TMI.2014.2303821 10.1016/j.ejrad.2020.109095 10.1007/s00330-020-07027-w 10.1016/j.carj.2018.02.002 10.1038/s41568-018-0016-5 10.1007/s00330-018-5674-x 10.1038/nature14539 10.1001/jama.2016.17216 10.1016/j.enbuild.2017.04.038 10.1016/j.eururo.2016.12.006 10.1016/j.eururo.2018.11.031 10.1259/bjr.20190929 10.1016/S1470-2045(18)30569-2 10.1016/S0140-6736(16)32401-1 10.1001/jamaoncol.2020.7456 10.1016/j.ejrad.2019.108662 10.5152/dir.2019.18537 10.1016/j.acra.2017.08.013 10.1016/S2589-7500(19)30123-2 10.1148/radiol.2019190938 10.1016/j.ejrad.2018.06.020 10.1097/EDE.0b013e3181c30fb2
European Radiology; Penzkofer T, Padhani AR et. al.
May 15th, 2021 - Artificial intelligence developments are essential to the successful deployment of community-wide, MRI-driven prostate cancer diagnosis. AI systems should ensure that the main benefits of biopsy avoidance are delivered while maintaining consistent...
Guidelines 393 results
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,
Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.
Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB
Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.
Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...
Drugs 341 results see all →
Clinicaltrials.gov 94,995 results
https://doi.org/10.2967/jnumed.120.258533
Journal of Nuclear Medicine : Official Publication, Socie... Treiber H, Koenig A et. al.
May 15th, 2021 - 177Lu-PSMA radioligand therapy (177Lu-PSMA-RLT) is a promising new therapeutic option for patients with metastasized castration-resistant prostate cancer (mCRPC). The spectrum of adverse events with this treatment has to be evaluated. Here, we des...
https://doi.org/10.2967/jnumed.121.262120
Journal of Nuclear Medicine : Official Publication, Socie... Barbato F, Fendler WP et. al.
May 15th, 2021 - Conventional imaging low-(LVD) versus high-volume disease (HVD) are associated with survival in metastatic hormone-sensitive prostate cancer (mHSPC) according to CHAARTED and STAMPEDE trials. We propose a compatible quantitative PSMA-PET framework...
https://doi.org/10.1007/s00345-021-03723-4 10.1097/CCO.0000000000000172 10.1093/annonc/mdv267 10.1038/nature05874 10.1158/1078-0432.CCR-13-1989 10.1093/nar/gkq1027 10.1146/annurev-pathol-012513-104715 10.1038/nrg2634 10.1002/pros.21276 10.1002/iub.1281 10.1038/onc.2011.624 10.1016/j.febslet.2015.04.037 10.1002/pros.22961 10.1093/nar/gni178 10.1038/onc.2012.55 10.1007/s11010-013-1882-5 10.1186/1479-5876-11-302 10.1038/nmeth.3014 10.1261/rna.036475.112 10.1038/bjc.2013.131 10.1177/1756287214555336 10.1186/1471-2490-13-58 10.1016/j.eururo.2016.08.002 10.1056/NEJMoa1315815 10.1016/j.biocel.2014.06.013 10.1158/0008-5472.CAN-15-0381 10.1038/nrurol.2015.13 10.1002/jcp.24510 10.1002/pros.22466 10.1093/clinchem/hvaa095
World Journal of Urology; Rönnau CGH, Fussek S et. al.
May 15th, 2021 - Prostate cancer (PCa) is a leading cause of cancer-related death. Upon androgen-deprivation therapy, the disease may progress further to castration-resistant PCa (CRPC) with a poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs, which pla...
https://doi.org/10.1002/cam4.3932
Cancer Medicine; Getaneh AM, Heijnsdijk EA et. al.
May 15th, 2021 - The introduction of multiparametric magnetic resonance imaging (mpMRI) and MRI-guided biopsy has improved the diagnosis of prostate cancer. However, it remains uncertain whether it is cost-effective, especially in a population-based screening stra...
https://doi.org/10.1007/s00330-021-08021-6 10.1016/j.eururo.2019.02.033 10.6004/jnccn.2018.0036 10.1016/j.juro.2016.06.079 10.1148/radiol.2019182946 10.1001/jamanetworkopen.2019.8427 10.1016/j.eururo.2020.06.015 10.1007/s00330-016-4635-5 10.1097/JU.0000000000001200 10.1056/NEJMoa1801993 10.1016/j.juro.2018.07.001 10.18632/oncotarget.26100 10.1007/s00330-017-4805-0 10.1109/TMI.2014.2303821 10.1016/j.ejrad.2020.109095 10.1007/s00330-020-07027-w 10.1016/j.carj.2018.02.002 10.1038/s41568-018-0016-5 10.1007/s00330-018-5674-x 10.1038/nature14539 10.1001/jama.2016.17216 10.1016/j.enbuild.2017.04.038 10.1016/j.eururo.2016.12.006 10.1016/j.eururo.2018.11.031 10.1259/bjr.20190929 10.1016/S1470-2045(18)30569-2 10.1016/S0140-6736(16)32401-1 10.1001/jamaoncol.2020.7456 10.1016/j.ejrad.2019.108662 10.5152/dir.2019.18537 10.1016/j.acra.2017.08.013 10.1016/S2589-7500(19)30123-2 10.1148/radiol.2019190938 10.1016/j.ejrad.2018.06.020 10.1097/EDE.0b013e3181c30fb2
European Radiology; Penzkofer T, Padhani AR et. al.
May 15th, 2021 - Artificial intelligence developments are essential to the successful deployment of community-wide, MRI-driven prostate cancer diagnosis. AI systems should ensure that the main benefits of biopsy avoidance are delivered while maintaining consistent...
News 6,567 results
https://www.medscape.com/viewarticle/950821
May 9th, 2021 - In the United States, cryoablation or freezing tissue to death is a primary treatment option for a variety of cancers, including those originating in or spread to the bone, cervix, eye, kidney, liver, lung, pancreas, prostate, and skin. Cryoablati...
https://www.medscape.com/viewarticle/950227
Apr 29th, 2021 - (Reuters Health) - Nearly 10 million screenings for three common cancers were missed in the U.S. because of the COVID-19 pandemic, a new study suggests. A comparison of monthly screening rates during the spring and summer of 2020 to rates during 2...
https://www.medscape.com/viewarticle/949688
Apr 25th, 2021 - A 73-year-old man with prostate cancer and hypertension came to see me for an incidental diagnosis of papillary thyroid microcarcinoma (PTMC). He had undergone fluorodeoxyglucose (FDG) PET with his oncology team because of a rising serum prostate-...
https://www.medscape.com/viewarticle/949819
Apr 25th, 2021 - NEW YORK (Reuters Health) - Loss of MAP3K7 protein expression, seen in approximately 40% of prostate cancer patients, is a major driver of prostate tumor aggressiveness and should be considered for inclusion in management algorithms, researchers s...
https://www.medscape.com/viewarticle/949979
Apr 25th, 2021 - Hormonal therapies for the treatment of hormone-dependent breast and prostate cancer could raise the risk for myocardial infarction (MI) and stroke, and patients need to be closely monitored to allow early detection and treatment of cardiovascular...
